Psychopharmacology of ADHD: Children and adolescents

Journal of Clinical Psychiatry

Volumn 59, Issue SUPPL. 7, 1998, Pages 42-49

  Findling, Robert L ^a,b   Dogin, Judith W ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Psychiatry ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; AMITRIPTYLINE; AMPHETAMINE; CHLORPROMAZINE; CLONIDINE; CLORGYLINE; DESIPRAMINE; DEXAMPHETAMINE; FLUOXETINE; GUANFACINE; HALOPERIDOL; IMIPRAMINE; METHYLPHENIDATE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NORTRIPTYLINE; PEMOLINE MAGNESIUM; PSYCHOSTIMULANT AGENT; THIORIDAZINE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANOREXIA; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL TRIAL; DRUG METABOLISM; GROWTH RETARDATION; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; LEUKOPENIA; LIVER TOXICITY; MOTOR DYSFUNCTION; NEUROTOXICITY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; STOMACH PAIN; SUBSTANCE ABUSE; SUSTAINED RELEASE PREPARATION; TREATMENT FAILURE;

ADOLESCENT; AGE FACTORS; AMPHETAMINES; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BUPROPION; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CYCLOHEXANOLS; DEXTROAMPHETAMINE; DRUG ADMINISTRATION SCHEDULE; FLUOXETINE; HUMANS; METHYLPHENIDATE; MONOAMINE OXIDASE INHIBITORS; PEMOLINE; SEROTONIN UPTAKE INHIBITORS;

EID: 0031869474     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (131)

1. Delay J, Deniker P, Harl JM. Utilisation en thérapeutique psychiatrique d'une phénothiazine d'action central élective (4560 RP). Ann Med Psychol 1952;110:112-117
2. Bradley C. The behavior of children receiving benzedrine. Am J Psychiatry 1937;94:577-585
3. Green WH. The treatment of attention-deficit hyperactivity disorder with nonstimulant medications. Child Adolesc Psychiatric Clin North Am 1995; 4:169-195
4. Greenhill LL. Attention-deficit hyperactivity disorder: the stimulants. Child Adolesc Psychiatric Clin North Am 1995;4:123-168
5. Spencer T, Biederman J, Wilens T, et al. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 1996;35:409-432
6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
7. Garfinkel BD, Amrami KK. Assessment and differential diagnosis of attention-deficit hyperactivity disorder. Child Adolesc Psychiatric Clin North Am 1992;1:311-324
8. American Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1991;30:I-III
9. Cantwell DP. Attention deficit disorder: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry 1996;35:978-987
10. Biederman J, Munir K, Knee D, et al. High rate of affective disorders in probands with attention deficit disorder and in their relatives: a controlled family study. Am J Psychiatry 1987;144:330-333
11. Biederman J, Faraone SV, Keenan K, et al. Further evidence for family-genetic risk factors in attention deficit hyperactivity disorder: patterns of comorbidity in probands and relatives in psychiatrically and pediatrically referred samples. Arch Gen Psychiatry 1992;49:728-738
12. Keller MB, Lavori PW, Beardslee WR, et al. The disruptive behavioral disorder in children and adolescents: comorbidity and clinical course. J Am Acad Child Adolesc Psychiatry 1992;31:204-209
13. Pliszka SR. Comorbidity of attention-deficit hyperactivity disorder and overanxious disorder. J Am Acad Child Adolesc Psychiatry 1992;31: 197-203
14. Butler SF, Arrendondo DE, McCloskey V. Affective comorbidity in children and adolescents with attention deficit hyperactivity disorder. Ann Clin Psychiatry 1995;7:51-55
15. American Academy of Pediatrics, Committee on Children with Disabilities and Committee on Drugs. Medication for children with attentional disorders. Pediatrics 1996;98:301-304
16. Jensen PS, Vitiello B, Leonard H, et al. Child and adolescent psychopharmacology: expanding the research base. Psychopharmacol Bull 1994;30: 3-8
17. Wilens TE, Biederman J. The stimulants. Psychiatr Clin North Am 1992; 15:191-222
18. Barkley RA. The effects of methylphenidate on the interactions of preschool ADHD children and their mothers. J Am Acad Child Adolesc Psychiatry 1988;27:336-341
19. Brown RT, Sexson SB. A controlled trial of methylphenidate in black adolescents: attentional, behavioral, and physiological effects. Clin Pediatr 1988;27:74-81
20. Klorman R, Coons HW, Borgstedt AD. Effects of methylphenidate on adolescents with a childhood history of attention deficit disorder, I: clinical findings. J Am Acad Child Adolesc Psychiatry 1987;26:363-367
21. Wolraich ML, Lindgren S, Stromquist A, et al. Stimulant medication use by primary care physicians in the treatment of attention deficit hyperactivity disorder. Pediatrics 1990;86:95-101
22. Popper CW. The story of four salts. J Child Adolesc Psychopharmacol 1994;4:217-223
23. Dulcan MK. Using psychostimulants to treat behavioral disorders of children and adolescents. J Child Adolesc Psychopharmacol 1990;1:7-20
24. Rapport MD, DuPaul GJ, Kelly KL. Attention deficit hyperactivity disorder and methylphenidate: the relationship between gross body weight and drug response in children. Psychopharmacol Bull 1989;25:285-290
25. Gualtieri CT, Wargin W, Kanoy R, et al. Clinical studies of methylphenidate serum levels in children and adults. J Am Acad Child Psychiatry 1982; 21:19-26
26. Gualtieri CT, Hicks RE, Patrick K, et al. Clinical correlates of methylphenidate blood levels. Ther Drug Monit 1984;6:379-392
27. Pelham WE, Swanson J, Furman MB, et al. Pemoline effects on children with ADHD: a time-response by dose-response analysis on classroom measures. J Am Acad Child Adolesc Psychiatry 1995;34:1504-1513
28. Physicians' Desk Reference. Montvale, NJ: Medical Economics; 1996
29. Amaya-Jackson L, Cantwell DP. Controversies in psychopharmacological management of attention deficit and related disorders. Int Pediatr 1991;6: 176-183
30. Barkley RA, DuPaul GJ, McMurray MB. Attention deficit disorder with and without hyperactivity: clinical response to three dose levels of methylphenidate. Pediatrics 1991;87:519-531
31. Pelham WE, Bender ME, Caddell J, et al. Methylphenidate and children with attention deficit disorder: dose effects on classroom academic and social behavior. Arch Gen Psychiatry 1985;42:948-952
32. Brown RT, Sleator EK. Methylphenidate in hyperkinetic children: differences in dose effects on impulsive behavior. Pediatrics 1979;64:408-411
33. Sprague RL, Sleator EK. Methylphenidate in hyperkinetic children: differences in dose effects on learning and social behavior. Science 1977;198: 1274-1276
34. Cylert (pemoline). Physicians' Desk Reference. Montvale, NJ: Medical Economics; 1997:415-416
35. Sallee FR, Stiller RL, Perel JM. Pharmacodynamics of pemoline in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 1992;31:244-251
36. Kent JD, Blader JC, Koplewicz HS, et al. Effects of late-afternoon methylphenidate administration on behavior and sleep in attention-deficit hyperactivity disorder. Pediatrics 1995;96:320-325
37. Stein MA, Blondis TA, Schnitzler ER, et al. Methylphenidate dosing: twice daily versus three times daily. Pediatrics 1996;98:748-756
38. Brown RT, Borden KA, Clingerman SR. Adherence to methylphenidate therapy in a pediatric population: a preliminary investigation. Psychopharmacol Bull 1985;21:28-36
39. Firestone P. Factors associated with children's adherence to stimulant medication. Am J Orthopsychiatry 1982;52:447-457
40. The Medical Letter. Adderall and other drugs for attention-deficit hyperactivity disorder. Med Lett Drug Ther 1994;36:109-110
41. Whitehouse D, Shah U, Palmer FB. Comparison of sustained-release and standard methylphenidate in the treatment of minimal brain dysfunction. J Clin Psychiatry 1980;41:282-285
42. Fitzpatrick PA, Klorman R, Brumaghim JT, et al. Effects of sustained-release and standard preparations of methylphenidate on attention deficit disorder. J Am Acad Child Adolesc Psychiatry 1992;31:226-234
43. Pelham WE, Greenslade KE, Vodde-Hamilton M, et al. Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline. Pediatrics 1990;86:226-237
44. Brown GL, Ebert MH, Mikkelsen EJ, et al. Behavior and motor activity response in hyperactive children and plasma amphetamine levels following a sustained release preparation. J Am Acad Child Psychiatry 1980;19: 225-239
45. Pelham WE, Sturges J, Hoza J, et al. Sustained release and standard methylphenidate effects on cognitive and social behavior in children with attention deficit disorder. Pediatrics 1987;80:491-501
46. Stevenson RD, Wolraich ML. Stimulant medication therapy in the treatment of children with attention deficit hyperactivity disorder. Pediatr Clin North Am 1989;36:1183-1197
47. Rosse RB, Licamele WL. Slow-release methylphenidate: problems when children chew tablets [letter]. J Clin Psychiatry 1984;45:525
48. Ahmann PA, Waltonen SJ, Olson KA, et al. Placebo-controlled evaluation of Ritalin side effects. Pediatrics 1993;91:1101-1106
49. Barkley RA, McMurray MB, Edelbrock CS, et al. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics 1990;86:184-192
50. Jacobvitz D, Sroufe LA, Stewart M, et al. Treatment of attentional and hyperactivity problems in children with sympathomimetic drugs: a comprehensive review. J Am Acad Child Adolesc Psychiatry 1990;29:677-688
51. Schertz M, Adesman AR, Alfieri NE, et al. Predictors of weight loss in children with attention deficit hyperactivity disorder treated with stimulant medication. Pediatrics 1996;98:763-769
52. Ballard JE, Boileau RA, Sleator EK, et al. Cardiovascular responses of hyperactive children to methylphenidate. JAMA 1976;236:2870-2874
53. Aman MG, Werry JS. The effects of methylphenidate and haloperidol on the heart rate and blood pressure of hyperactive children with special reference to time of action. Psychopharmacology (Berl) 1975;43:163-168
54. Brown RT, Wynne ME, Slimmer LW. Attention deficit disorder and the effect of methylphenidate on attention, behavioral, and cardiovascular functioning. J Clin Psychiatry 1984;45:473-476
55. Safer D, Allen R, Barr E. Depression of growth in hyperactive children on stimulant drugs. N Engl J Med 1972;287:217-220
56. Hechtman L, Weiss G, Perlman T. Young adult outcome of hyperactive children who received long-term stimulant treatment. J Am Acad Child Adolesc Psychiatry 1984;23:261-269
57. Klein RG, Mannuzza S. Hyperactive boys almost grown up, III: methylphenidate effects on ultimate height. Arch Gen Psychiatry 1988;45: 1131-1134
58. Vincent J, Varley CK, Leger P. Effects of methylphenidate on early adolescent growth. Am J Psychiatry 1990;147:501-502
59. Spencer TJ, Biederman J, Harding M, et al. Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays? J Am Acad Child Adolesc Psychiatry 1996;35:1460-1469
60. Lowe TL, Cohen DJ, Detlor J, et al. Stimulant medications precipitate Tourette's syndrome. JAMA 1982;247:1729-1731
61. Singer HS, Brown J, Quaskey S, et al. The treatment of attention-deficit hyperactivity disorder in Tourette's Syndrome: a double-blind, placebo-controlled study with clonidine and desipramine. Pediatrics 1995;95: 74-81
62. Gadow KD, Sverd J, Sprafkin J, et al. Efficacy of methylphenidate for attention-deficit hyperactivity disorder in children with tic disorder. Arch Gen Psychiatry 1995;52:444-455
63. Lipkin PH, Goldstein IJ, Adesman AR. Tics and dyskinesias associated with stimulant treatment in attention-deficit hyperactivity disorder. Arch Pediatr Adolesc Med 1994;148:863-871
64. Sallee FR, Stiller RL, Perel JM, et al. Pemoline-induced abnormal involuntary movements. J Clin Psychopharmacol 1989;9:125-129
65. Nehra A, Mullick F, Ishak KG, et al. Pemoline-associated hepatic injury. Gastroenterology 1990;99:1517-1519
66. Berkovitch M, Pope E, Phillips J, et al. Pemoline-associated fulminant liver failure: testing the evidence for causation. Clin Pharmacol Ther 1995; 57:696-698
67. Birmaher B, Greenhill LL, Cooper TB, et al. Sustained release methylphenidate: pharmacokinetic studies in ADDH males. J Am Acad Child Adolesc Psychiatry 1989;28:768-772
68. Collier CP, Soldin SJ, Swanson JM, et al. Pemoline pharmacokinetics and long term therapy in children with attention deficit disorder and hyperactivity. Clin Pharmacokinet 1985;10:269-278
69. Hungund BL, Perel JM, Hurwic MJ, et al. Pharmacokinetics of methylphenidate in hyperactive children. Br J Clin Pharmacol 1979;8:571-576
70. Sallee F, Stiller R, Perel J, et al. Oral pemoline kinetics in hyperactive children. Clin Pharmacol Ther 1985;37:606-609
71. Shaywitz S, Hunt RD, Jatlow P, et al. Psychopharmacology of attention deficit disorders: pharmacokinetic, neuroendocrine, and behavioral measures following acute and chronic treatment with methylphenidate. Pediatrics 1982;69:688-694
72. Winsberg BG, Kupietz SS, Sverd J, et al. Methylphenidate oral dose plasma concentrations and behavioral response in children. Psychopharmacology 1982;76:329-332
73. Brosen K. Recent developments in hepatic drug oxidation: implications for clinical pharmacokinetics. Clin Pharmacokinet 1990;18:220-229
74. Dahl ML, Bertilsson L. Genetically variable metabolism of antidepressant and neuroleptic drugs in man. Pharmacogenetics 1993;3:61-70
75. Pollock BG. Recent developments in drug metabolism of relevance to psychiatrists. Harvard Rev Psychiatry 1994;2:204-213
76. Meyer UA, Amrein R, Balant LP, et al. Antidepressants and drug metabolizing enzymes: expert group report. Acta Psychiatr Scand 1996;93:71-79
77. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996;153:311-320
78. Wilens TE, Spencer T, Biederman J, et al. Combined pharmacotherapy: an emerging trend in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 1995;34:110-112
79. Parraga HC, Kelly DP, Parraga MI, et al. Combined psychostimulant and tricyclic antidepressant treatment of Tourette's syndrome and comorbid disorders in children. J Child Adolesc Psychopharmacol 1994;4: 113-122
80. Findling RL. Open-labeled treatment of comorbid depression and attentional disorders with co-administration of serotonin re-uptake inhibitors and psychostimulants in children, adolescents, and adults: a case series. J Child Adolesc Psychopharmacol. In press
81. Gross MD. Buspirone in ADHD with ODD [letter]. J Am Acad Child Adolesc Psychiatry 1995;34:1260
82. Carlson GA, Rapport MD, Kelly KL, et al. The effects of methylphenidate and lithium on attention and activity level. J Am Acad Child Adolesc Psychiatry 1992;31:262-270
83. Wozniak J, Biederman J. A pharmacological approach to the quagmire of comorbidity in juvenile mania. J Am Acad Child Adolesc Psychiatry 1996;35:826-828
84. Bourrié M, Meunier V, Berger Y, et al. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 1996;277:321-332
85. Ho JW, Moody DE. Determination of tolbutamide hydroxylation in rat liver microsomes by high-performance liquid chromatography: effect of psychoactive drugs on in vitro activity. Life Sci 1993;52:21-28
86. Lin LY, Fujimoto M, Distefano EW, et al. Selective mechanism-based inactivation of rat CYP2D by 4-allyloxymethamphetamine. J Pharmacol Exp Ther 1996;277:595-603
87. Law MYL, Moody DE. Urinary excretion of amphetamine and 4′-hydroxyamphetamine by Sprague Dawley and Dark Agouti rats. Life Sci 1994;54:1073-1079
88. Geertsen S, Foster BC, Wilson DL, et al. Metabolism of methoxyphenamine and 2-methoxyamphetamine in P450 2D6-transfected cells and cell preparations. Xenobiotica 1995;25:895-906
89. Borcherding BG, Keysor CS, Cooper TB, et al. Differential effects of methylphenidate and dextroamphetamine on the motor activity level of hyperactive children. Neuropsychopharmacology 1989;2:253-263
90. Borcherding BG, Keysor CS, Rapoport JL, et al. Motor/vocal tics and compulsive behaviors on stimulant drugs: is there a common vulnerability? Psychiatry Res 1990;33:83-94
91. Elia J, Borcherding BG, Rapoport JL, et al. Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true non-responders? Psychiatry Res 1991;36:141-155
92. Elia J. Drug treatment for hyperactive children: therapeutic guidelines. Drugs 1993;46:863-871
93. Quinn PO, Rapoport JL. One-year follow-up of hyperactive boys treated with imipramine or methylphenidate. Arch Gen Psychiatry 1975;132: 241-245
94. Rapoport JL, Quinn PO, Bradbard G, et al. Imipramine and methylphenidate treatments of hyperactive boys: a double-blind comparison. Arch Gen Psychiatry 1974;30:789-793
95. Werry JS, Aman MG, Diamond E. Imipramine and methylphenidate in hyperactive children. J Child Psychol Psychiatry 1980;21:27-35
96. Waizer J, Hoffman SP, Polizos P, et al. Outpatient treatment of hyperactive school children with imipramine. Am J Psychiatry 1974;131: 587-591
97. Greenberg LM, Yellin AM. Blood pressure and pulse changes in hyperactive children treated with imipramine and methylphenidate. Am J Psychiatry 1975;132:1325-1326
98. Gastfriend DR, Biederman J, Jellinek MS. Desipramine in the treatment of adolescents with attention deficit disorder. Am J Psychiatry 1984;141:906-908
99. Biederman J, Baldessarini RJ, Wright V, et al. A double-blind placebo controlled study of desipramine in the treatment of ADD, I: efficacy. J Am Acad Child Adolesc Psychiatry 1989;28:777-784
100. The Medical Letter. Sudden death in children treated with a tricyclic antidepressant. Med Lett Drugs Ther 1990;32:53
101. Riddle MA, Geller B, Ryan N. Case study: another sudden death in a child treated with desipramine. J Am Acad Child Adolesc Psychiatry 1993;32:792-797
102. Wagner KD, Fershtman M. Potential mechanism of desipramine-related sudden death in children. Psychosomatics 1993;34:80-82
103. Kupietz SS, Balka EB. Alterations in the vigilance performance of children receiving amitriptyline and methylphenidate pharmacotherapy. Psychopharmacology 1976;50:29-33
104. Wilens TE, Biederman J, Geist DE, et al. Nortriptyline in the treatment of ADHD: a chart review of 58 cases. J Am Acad Child Adolesc Psychiatry 1993;32:343-349
105. Yepes LE, Balka EB, Winsberg BG, et al. Amitriptyline and methylphenidate treatment of behaviorally disordered children. J Child Psychol Psychiatry 1977;18:39-52
106. Zametkin A, Rapoport JL, Murphy DL, et al. Treatment of hyperactive children with monoamine oxidase inhibitors, I: clinical efficacy. Arch Gen Psychiatry 1985;42:962-966
107. Barrickman L, Perry PJ, Allen AJ, et al. Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995;34:649-657
108. Casat CD, Pleasants DZ, Schroeder DH, et al. Bupropion in children with attention deficit disorder. Psychopharmacol Bull 1989;25:198-201
109. Clay TH, Gualtieri CT, Evans RW, et al. Clinical and neuropsychological effects of the novel antidepressant bupropion. Psychopharmacol Bull 1988;24:143-148
110. Conners CK, Casat CD, Gualtieri CT, et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 1996;35:1314-1321
111. Barrickman L, Noyes R, Kuperman S, et al. Treatment of ADHD with fluoxetine: a preliminary trial. J Am Acad Child Adolesc Psychiatry 1991; 30:762-767
112. Olvera RL, Pliszka SR, Luh J, et al. An open trial of venlafaxine in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. J Child Adolesc Psychopharmacol 1996;6:241-250
113. Adler LA, Resnick S, Kunz M, et al. Open-label trial of venlafaxine in adults with attention deficit disorder. Psychopharmacol Bull 1995;31: 785-788
114. Hedges D, Reimherr FW, Rogers A, et al. An open trial of venlafaxine in adult patients with attention deficit hyperactivity disorder. Psychopharmacol Bull 1995;31:779-783
115. Findling RL, Schwartz MA, Flannery DJ, et al. Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial. J Clin Psychiatry 1996;57:184-189
116. Derivan A, Aguiar L, Preskorn S, et al. A study of venlafaxine in children and adolescents with conduct disorder. Presented at the American Academy of Child and Adolescent Psychiatry Annual Meeting; October 1995; New Orleans, La
117. Hunt RD, Minderaa RB, Cohen DJ. Clonidine benefits children with attention deficit disorder and hyperactivity: report of a double-blind placebo-crossover therapeutic trial. J Am Acad Child Adolesc Psychiatry 1985;24:617-629
118. Hunt RD, Minderaa RB, Cohen DH. The therapeutic effect of clonidine in attention deficit disorder with hyperactivity: a comparison with placebo and methylphenidate. Psychopharmacol Bull 1986;22:229-236
119. Hunt RD. Treatment effects of oral and transdermal clonidine in relation to methylphenidate: an open pilot study in ADD-H. Psychopharmacol Bull 1987;23:111-114
120. Steingard R, Biederman J, Spencer T, et al. Comparison of clonidine response in the treatment of attention-deficit hyperactivity disorder with and without comorbid tic disorders. J Am Acad Child Adolesc Psychiatry 1993;32:350-353
121. Hunt RD, Capper L, O'Connell P. Clonidine in child and adolescent psychiatry. J Child Adolesc Psychopharmacol 1990;1:87-102
122. Hunt RD, Arnsten AFT, Asbell MD. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995;34:50-54
123. Prince JB, Wilens TE, Biederman J, et al. Clonidine for sleep disturbances associated with attention-deficit hyperactivity disorder: a systematic chart review of 62 cases. J Am Acad Child Adolesc Psychiatry 1996; 35:599-605
124. Rubinstein S, Silver LB, Licamele WL. Clonidine for stimulant-related sleep problems [letter]. J Am Acad Child Adolesc Psychiatry 1994;33: 281-282
125. Chandran KSK. ECG and clonidine [letter]. J Am Acad Child Adolesc Psychiatry 1994;33:1351-1352
126. Maloney MJ, Schwam TJ. Clonidine and sudden death [letter]. Pediatrics 1995;96:1176-1177
127. Gittelman-Klein R, Klein DF, Katz S, et al. Comparative effects of methylphenidate and thioridazine in hyperkinetic children, I: clinical results. Arch Gen Psychiatry 1976;33:1217-1231
128. Werry JS, Weiss G, Douglas V, et al. Studies on the hyperactive child, III: the effects of chlorpromazine upon behavior and learning ability. J Am Acad Child Psychiatry 1966;5:292-312
129. Werry JS, Aman MG. Methylphenidate and haloperidol in children: effects on attention, memory, and activity. Arch Gen Psychiatry 1975;32: 790-795
130. Teicher MH, Glod CA. Neuroleptic drugs: indications and guidelines for their rational use in children and adolescents. J Child Adolesc Psychopharmacol 1990;1:33-56
131. Gualtieri CT, Quade D, Hicks RE, et al. Tardive dyskinesia and other clinical consequences of neuroleptic treatment in children and adolescents. Am J Psychiatry 1984;141:20-23